Sign In
Buy OPRX
$4.95
-0.330 (-6.25%)
At Close: Jun 03, 2026
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Lags Revenue Estimates
07:34pm, Wednesday, 04'th May 2022
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -200% and 0.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sapiens (SPNS) Beats Q1 Earnings and Revenue Estimates
12:15pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Sapiens (SPNS) delivered earnings and revenue surprises of 14.81% and 0.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UPDATE – Surveyed Physicians Say Access Challenges Impact Their Care Plans for up to 33% of Patients
09:33pm, Wednesday, 20'th Apr 2022 GlobeNewswire Inc.
ROCHESTER, Mich., April 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay o
1 in 3 Surveyed Physicians Say They Would Make a Different Treatment Choice If Medication Access Was Not a Factor
01:17pm, Tuesday, 19'th Apr 2022 GlobeNewswire Inc.
ROCHESTER, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay o
How to Find New Stocks for Your Portfolio
02:00pm, Wednesday, 06'th Apr 2022 The Motley Fool
I like to read articles by people who aren't just bullish -- they've bought shares.
Financial Times Ranks OptimizeRx Amongst Americas’ Fastest-Growing Companies for the Third Consecutive Year
03:00pm, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.
OptimizeRx grew 2021 revenue by 42% year-over-year, spotlighting the rapid growth from the convergence of technology and healthcare OptimizeRx grew 2021 revenue by 42% year-over-year, spotlighting the
OptimizeRx Corporation (OPRX) Rises From The Low: Could It Be A Catbird Seat?
03:30pm, Saturday, 26'th Feb 2022 Stocks Register
OptimizeRx Corporation (NASDAQ:OPRX) concluded the trading at $45.19 on Friday, February 25 with a rise of 5.17% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $42.97 and 5Y monthly beta was reading 0.57 with its price kept floating in the range … OptimizeRx Corporation (OPRX) Rises From The Low: Could It Be A Catbird Seat? Read More »
OptimizeRx Corporation (OPRX) Q4 2021 Earnings Call Transcript
01:01pm, Friday, 25'th Feb 2022 The Motley Fool
OPRX earnings call for the period ending December 31, 2021.
OptimizeRx Corporation (OPRX) Q4 2021 Earnings Call Transcript
01:01pm, Friday, 25'th Feb 2022 The Motley Fool
OPRX earnings call for the period ending December 31, 2021.
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
10:30pm, Thursday, 24'th Feb 2022 Zacks Investment Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 22.22% and 1.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx's (OPRX) CEO William Febbo on Q4 2021 Results - Earnings Call Transcript
10:12pm, Thursday, 24'th Feb 2022
OptimizeRx's (OPRX) CEO William Febbo on Q4 2021 Results - Earnings Call Transcript
OptimizeRx Non-GAAP EPS of $0.22 beats by $0.18, revenue of $20.3M beats by $5.5M
09:49pm, Thursday, 24'th Feb 2022 Seeking Alpha
OptimizeRx press release (NASDAQ:OPRX): Q4 Non-GAAP EPS of $0.22 beats by $0.18.Revenue of $20.3M (+23.6% Y/Y) beats by $5.5M.
OptimizeRx Reports Fourth Quarter and Full Year 2021 Financial Results, Revenue Increased 42%, Demand from Large Pharma Gains Momentum
09:01pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
ROCHESTER, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on t
OptimizeRx Reports Fourth Quarter and Full Year 2021 Financial Results, Revenue Increased 42%, Demand from Large Pharma Gains Momentum
09:01pm, Thursday, 24'th Feb 2022 GlobeNewswire
ROCHESTER, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the fourth quarter and full year ended December 31, 2021.
